Telo Genomics (TELO.V) was granted three of its pending patent applications today, according to a press release.
The company already has patents pertaining to hematological cancers in the United States and Alzheimer’s disease in the United States and Canada. Their United States patent application on liquid biopsy is still pending.
“The issuance of three additional final patents further augments Telo’s already-strong IP portfolio. Blood cancers and liquid biopsy are at the core of the company’s commercialization program. The issuance of these patents assures the long-term protection of the TeloView platform as a prognostic/diagnostic tool for these diseases,” said Sabine Mai, Telo director and chair of the clinical and scientific advisory board.
Specifically, these patents include:
- Diagnostic methods for hematological disorders (hematological cancers) (Canada);
- Methods for characterizing and isolating circulating tumour cell subpopulations (liquid biopsy) (Canada);
- Methods of diagnosing Alzheimer’s disease (Europe).
The company has acquired intellectual property protection in jurisdictions around the world and owns a portfolio of patents and pending patent applications in the United States, Canada and the European Union. The IP covers their core technology and its applications. TeloView is trademarked in the United States, Canada, Europe and Israel, in addition to the company’s existing and pending intellectual property.
In other news, the company reports that Leede Jones Gable and Mackie Research Corp. have exercised 5,026,800 of clients’ and brokers’ warrants for $944,180 and neither Leede nor Mackie will be soliciting further warrant exercises.
—Joseph Morton
